Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer

Executive Summary

NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.

You may also be interested in...



COVID-19: US ACTIV Study Expands To Include Three Repurposed Drugs

Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.

Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

ACTIV Picks Potential COVID-19 Therapeutics To Be Tested In Master Protocol Trials

Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel